Bupropion and Isavuconazonium Interaction

Understanding the Bupropion and Isavuconazonium Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Bupropion belongs to the Norepinephrine-Dopamine Reuptake Inhibitor (NDRI) class and Isavuconazonium belongs to the Azole Antifungal class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking isavuconazonium can lower the amount of bupropion in your system, making the medication less effective. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Bupropion has 35 total documented interactions on file in this dataset, and Isavuconazonium has 9. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to increase your dose of bupropion to ensure it still works correctly. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Bupropion or Isavuconazonium based on a web page, speak with your prescriber or pharmacist before making any change.